Introduction
Hematopoietic transplantation from human leukocyte antigen (HLA) haplotypemismatched (haploidentical) donors is an established treatment for patients with high-risk acute leukemia who do not have a matched donor. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] In haploidentical, T cell-depleted peripheral blood stem cell transplants without post transplant graft-versus-host disease (GvHD) prophylaxis, [3] [4] [5] donor Natural Killer (NK) cells play a beneficial role in outcomes. [13] [14] [15] [16] [17] Human NK cells possess clonally distributed, inhibitory receptors termed 'Killer cell immunoglobulin-like receptors' (KIRs) that recognize epitopes shared by groups of HLA class I alleles (KIR ligands). 18-20 KIR2DL1 recognizes haplotypes that contain the main inhibitory KIR genes and the activating KIR2DS4 gene (however a KIR2DS4 deletion variant allele encodes for a non-functional receptor in up to ~80% of individuals). 32 The others are either heterozygous or homozygous for Group B KIR haplotypes that carry not only inhibitory KIR genes but also various combinations of activating KIR genes (KIR2DS1, 2, 3, 5 and 3DS1) . Little is known about their ligands except that KIR2DS1 binds HLA-C group 2 molecules. 33, 34 In vitro studies showed KIR2DS1 plays a role in NK cell killing of allogeneic targets that express HLA-C2.
27, [34] [35] [36] [37] Moreover, in clinical studies activating KIRs were found to be associated with less leukemia relapse in matched unrelated and haploidentical transplants [38] [39] [40] [41] [42] [43] and with protection against AIDS progression and HCV infection. 44, 45 In the present study we investigated the role of donor activating KIRs in haploidentical transplants for acute leukemia grouped according to presence or absence of donor-versus-recipient NK cell alloreactivity. We found that transplantation from donors who exerted donor-versus-recipient NK cell alloreactivity and carried KIR2DS1 and/or KIR3DS1 genes was associated with markedly reduced non-relapse mortality (NRM), which was largely infection-related, and with significantly better event-free survival (EFS).
Interestingly, our in vitro analyses showed KIR2DS1 binding to HLA-C2 up-regulated inflammatory cytokine production by alloreactive NK cells in response to infectious challenges.
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From 7 recipient, 2) donors possessed the relevant inhibitory KIR gene(s) for missing-self recognition of recipient targets (KIR2DL2 and/or KIR2DL3 were present in everyone, KIR2DL1 was absent in ~3% of individuals and KIR3DL1 was absent in ~10%), 31 3)
donors possessed alloreactive NK cell clones against recipient targets (see "NK cell isolation, cloning and allocytotoxicity assay"). As our previous analyses in large numbers of individuals had shown they possessed alloreactive NK clones against HLA-C group mismatched targets, 16 in the present study NK cell cloning and allocytotoxicity assays were not considered necessary and were therefore not routinely performed in HLA-C group mismatched transplant donors (however, this information was available for 29 of the 60 HLA-C group mismatched transplant donors included in the present study). Thus, HLA typing and donor KIR genotyping were considered sufficient to define HLA-C group mismatched transplant donors as NK alloreactive. As previous analyses had shown alloreactive NK clones against HLA-Bw4 mismatched targets are undetectable in ~1/3 of KIR3DL1-positive individuals, 16 NK cell cloning and allocytotoxicity assays were considered necessary and were therefore routinely performed.
KIR genotyping
Genomic DNA was prepared from donor peripheral blood mononuclear cells (PBMCs) using the Nucleospin Tissue Kit (Macherey-Nagel, Düren, Germany). KIR genes were typed as described elsewhere 16 or with the Olerup SSP KIR Genotyping kit (Olerup SSP AB, Stockholm, Sweden). KIR genes of the centromeric and telomeric segments of A and B haplotypes 48-50 were analyzed as described elsewhere. 39 Figure 1 shows the genomic organization of the KIR locus. Donor KIR genotypes are indicated as A/A when they did not contain B haplotypes; the centromeric segment is termed "Cen-A/A" and the telomeric "Tel-A/A". Donor KIR genotypes are indicated as B/x when they contained at Clones exhibiting >30% lysis were scored as alloreactive.
Flow Cytometry
FACSCanto flow cytometer with FACSDiva software (BD Biosciences, San José, CA) and FlowJo software (Tree Star Inc., Ashland, OR) were used for multicolor immunofluorescence analyses and intracellular staining.
NK clones that were alloreactive against HLA-C1 missing cell targets were phenotyped with the following monoclonal antibodies (mAbs): anti-CD56-APC (clone NKH-1, IgG1), anti-CD3-PE-Cy7 (clone UCHT1, IgG1) (Beckman Coulter Inc., Fullerton, CA) and anti-KIR2DL2/L3/S2-FITC (clone CH-L, IgG2b) (BD Biosciences) in combination with either anti-KIR2DL1/S1-PE (clone EB6B, IgG1), anti-KIR3DL1/S1-PE (clone Z27, IgG1), 
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